FDA Reprint Policy Expands To Clinical Practice Guidelines, Medical Reference Texts
This article was originally published in The Pink Sheet Daily
FDA has revised, but not loosened, its 2009 final guidance on good reprint practices for distribution of journal articles on unapproved uses of approved drugs and devices.
You may also be interested in...
US FDA proposes studies to look at the impact of disclosure of a product’s secondary claims and biosimilar designation; disclosure about unapproved uses; and the impact of citing a drug’s multiple indications in TV ads.
Office of Criminal Investigations Director George Karavetsos talks about the Park Doctrine and off-label enforcement in an interview.
Office of Criminal Investigations Director George Karavetsos talks about the Park Doctrine and off-label enforcement in interview with “The Pink Sheet.”